Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Abstract As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies, comparing reactogenicity, immunogenicity and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ian McDonald, Sam M. Murray, Catherine J. Reynolds, Daniel M. Altmann, Rosemary J. Boyton
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5f7d4b1caeb145c2af24bb7f27b2e13e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f7d4b1caeb145c2af24bb7f27b2e13e
record_format	dspace
spelling	oai:doaj.org-article:5f7d4b1caeb145c2af24bb7f27b2e13e2021-12-02T15:43:17ZComparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-210.1038/s41541-021-00336-12059-0105https://doaj.org/article/5f7d4b1caeb145c2af24bb7f27b2e13e2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00336-1https://doaj.org/toc/2059-0105Abstract As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies, comparing reactogenicity, immunogenicity and efficacy across different vaccine platforms for comparative evaluation (updated to March 22, 2021). Twenty-three NHP and 32 human studies are included. Vaccines result in mostly mild, self-limiting adverse events. Highest spike neutralizing antibody (nAb) responses are identified for the mRNA-1273-SARS-CoV and adjuvanted NVX-CoV2373-SARS-CoV-2 vaccines. ChAdOx-SARS-CoV-2 produces the highest T cell ELISpot responses. Pre-existing nAb against vaccine viral vector are identified following AdH-5-SARS-CoV-2 vaccination, halving immunogenicity. The mRNA vaccines depend on boosting to achieve optimal immunogenicity especially in the elderly. BNT162b2, and mRNA-1273 achieve >94%, rAd26/5 > 91% and ChAdOx-SARS-CoV-2 > 66.7% efficacy. Across different vaccine platforms there are trade-offs between antibody binding, functional nAb titers, T cell frequency, reactogenicity and efficacy. Emergence of variants makes rapid mass rollout of high efficacy vaccines essential to reduce any selective advantage.Ian McDonaldSam M. MurrayCatherine J. ReynoldsDaniel M. AltmannRosemary J. BoytonNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ian McDonald Sam M. Murray Catherine J. Reynolds Daniel M. Altmann Rosemary J. Boyton Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
description	Abstract As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies, comparing reactogenicity, immunogenicity and efficacy across different vaccine platforms for comparative evaluation (updated to March 22, 2021). Twenty-three NHP and 32 human studies are included. Vaccines result in mostly mild, self-limiting adverse events. Highest spike neutralizing antibody (nAb) responses are identified for the mRNA-1273-SARS-CoV and adjuvanted NVX-CoV2373-SARS-CoV-2 vaccines. ChAdOx-SARS-CoV-2 produces the highest T cell ELISpot responses. Pre-existing nAb against vaccine viral vector are identified following AdH-5-SARS-CoV-2 vaccination, halving immunogenicity. The mRNA vaccines depend on boosting to achieve optimal immunogenicity especially in the elderly. BNT162b2, and mRNA-1273 achieve >94%, rAd26/5 > 91% and ChAdOx-SARS-CoV-2 > 66.7% efficacy. Across different vaccine platforms there are trade-offs between antibody binding, functional nAb titers, T cell frequency, reactogenicity and efficacy. Emergence of variants makes rapid mass rollout of high efficacy vaccines essential to reduce any selective advantage.
format	article
author	Ian McDonald Sam M. Murray Catherine J. Reynolds Daniel M. Altmann Rosemary J. Boyton
author_facet	Ian McDonald Sam M. Murray Catherine J. Reynolds Daniel M. Altmann Rosemary J. Boyton
author_sort	Ian McDonald
title	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
title_short	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
title_full	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
title_fullStr	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
title_full_unstemmed	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
title_sort	comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against sars-cov-2
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5f7d4b1caeb145c2af24bb7f27b2e13e
work_keys_str_mv	AT ianmcdonald comparativesystematicreviewandmetaanalysisofreactogenicityimmunogenicityandefficacyofvaccinesagainstsarscov2 AT sammmurray comparativesystematicreviewandmetaanalysisofreactogenicityimmunogenicityandefficacyofvaccinesagainstsarscov2 AT catherinejreynolds comparativesystematicreviewandmetaanalysisofreactogenicityimmunogenicityandefficacyofvaccinesagainstsarscov2 AT danielmaltmann comparativesystematicreviewandmetaanalysisofreactogenicityimmunogenicityandefficacyofvaccinesagainstsarscov2 AT rosemaryjboyton comparativesystematicreviewandmetaanalysisofreactogenicityimmunogenicityandefficacyofvaccinesagainstsarscov2
_version_	1718385809363566592

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Ejemplares similares